

Carglumic Acid Tablets for Oral Suspension Patient Referral Form

Fax: 855-813-2039 Phone: 888-991-1330

	Please select one:	Ne	wly Prescribed P	atient P	Patient Currently on	Carglum	ic Acid			
	Last Name: First Name:			SSN:	N:			M	O F	
Patient Information *Please print	Address:			City:		State:		Zip:		
	Phone: Day #	Evenir	 ng #:		Cell #:		Preferred met Day #	thod of Contac Evening		Cell#
	DOB:	3: Weight Lbs:			Kg:	Height:		BSA:		
	If Patient is a Minor, Guardian/Parent	Relation to Patient:								
	Emergency Contact:	Phone #:								
Insurance Information	Primary Insurance Co. Name:			-			Phone #:			
	Policy Holder Name:			Policy #:			Group #:			
	Prescription Card Name:						Phone #:			
	Policy #:						Group #:			
	Secondary Insurance Co. Name:						Phone #:			
	Policy Holder Name:			Policy #:			Group #:			
Physician Information	Prescriber Name/Title:			-						
	NPI: DEA:	Medicaid U	IPIN:		State Licer	nse #:				
Infor	Address:						<u> </u>			
cian	City:				State:	Zip:				
hysi	Name of Contact Person:						Phone:			
Δ.,	Physician Email:						Fax:			
Prescription	Carglumic Acid Tablets for Oral Suspension, 200mg SIG: Take mg; equaling tablets per day									-
Medical Necessity	Please check applicable ICD-10 cod									
	NAGS Deficiency (E72.20)									
	NKDA	Allergi	es:							
edica	Baseline Ammonia Level:	_ umol	/L Test	: Date:	·					
M	Comment Madienties									
Lortify	Concurrent Medication: Viam prescribing Carglumic Acid fort									
Date Wi	ritten:e as Written:	_	Substitu	tion Allowed:						
(Stampe	d Signatures Are Not Valid)							CARA	C DV	200
	This Prescription F	orm is	-	FAXED to A	lnovo @855-813	3-2039	E R	orm: CARA affective:12 devision: 258-v3	/10/2	2021

Patient Marketing Opt-In Authorization

From time to time, Eton Pharmaceuticals, the marketer of Carglumic Acid may provide useful patient information or updates to our pharmacy services and offerings. By signing below and providing your contact information, you authorize Eton Pharmaceuticals and the companies working with Eton Pharmaceuticals to provide you with information, resources, and communication regarding your treatment. You agree that Eton Pharmaceuticals may contact you via email, direct mail, text, or phone call. Additionally, you agree that we may contact you and invite you to share your opinions regarding products, programs, and services. Eton Pharmaceuticals respects your personal information. All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained here. We encourage you to read our Privacy Notice www.carglumicacid.com. You may opt out of further communications at any time by calling 1-888-991-1330.

Patient/Guardian Signature	Date:		
Mailing Address:			
Cell:	Email:		

IMPORTANT SAFETY INFORMATION AND INDICATIONS

- Carglumic Acid tablets are for oral suspension and must be mixed in water before taking. Carglumic acid should **not be** mixed in any food or liquid other than water.
- **Do not** swallow Carglumic Acid tablets whole.
- **Do not** crush Carglumic Acid tablets.
- Take Carglumic Acid right before meals or feedings.

Adverse Reactions

Most common adverse reactions are vomiting, abdominal pain, pyrexia, tonsillitis, anemia, diarrhea, ear infection, infections, nasopharyngitis, hemoglobin decreased, and headache. These are not all the adverse reactions reported with Carglumic Acid.

Please visit www.carglumicacid.com for more information.

You are encouraged to report negative side effects of prescription drugs to Eton Pharmaceuticals at 1-855-224-0233, or FDA at 1-800-FDA-1088, or visit www.fda.gov/safety/medwatch.

Please see the Full Prescribing Information, including Instructions for Use, for Carglumic Acid.

INDICATIONS

Carglumic acid tablets for oral suspension are indicated in pediatric and adult patients as:

- Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency.
- Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency.

Form:CARAC.RX.208 Effective: 12/10/2021 Revision: 8/3/2023 1258-v3